Skip to main content
PAINWeek 2026 Main banner

Emerging Paradigms and Future Directions

EPF-02 - Innovations in Naloxone and Buprenorphine: Shaping the Future of Opioid Use Disorder Treatment

Wednesday, September 9, 2026
11:10 AM - 12:00 PM PDT

    Co-Presenter(s)

  • William Amarquaye, PharmD

    Clinical Pharmacist
    Tampa General Hospital
    Tampa General Hospital
    Valrico, Florida

  • Eugene Vortsman, DO

    Emergency and Addiction Medicine physician
    Northwell Health
    Zucker School of Medicine at Hofstra
    New York, New York

Explore the latest advancements in Naloxone and Buprenorphine, focusing on how these innovations are improving outcomes for individuals with opioid use disorder (OUD). Attendees will learn about new delivery methods, long-acting formulations, and strategies to increase access and adherence to these life-saving medications.

Learning Objectives:

  • Analyze emerging delivery systems for Naloxone, such as nasal sprays and auto-injectors, and their impact on accessibility.
  • Evaluate the benefits of long-acting Buprenorphine formulations in improving patient outcomes and adherence.
  • Address barriers to access and develop strategies to enhance patient adherence to Naloxone and Buprenorphine treatments.
  • Explore innovative approaches for addiction specialists and policymakers to leverage these medications in improving care for individuals with opioid use disorder.
  • Discuss policy and regulatory updates that influence the use of Naloxone and Buprenorphine in combating the opioid crisis.